Literature DB >> 28438876

Thrombotic Microangiopathy Following Chemotherapy with S-1 and Cisplatin in a Patient with Gastric Cancer: A Case Report.

Jun Muto1, Hiroshi Kishimoto2, Yasuo Kaizuka3, Mitsuru Kinjo4, Hidefumi Higashi5, Fumiaki Kishihara5.   

Abstract

BACKGROUND: Thrombotic microangiopathy (TMA) represents a spectrum of serious disorders characterized by occlusive microvascular thrombosis, thrombocytopenia and end-organ damage. TMA is associated with a broad range of conditions and is also a well-described complication of both cancer and its treatment. CASE REPORT: A 77-year-old Japanese woman underwent S-1 and cisplatin chemotherapy for treatment of advanced gastric cancer with multiple lymph node and liver metastases. She was found with severe anemia and thrombocytopenia during the third course of chemotherapy. She was diagnosed with TMA based on thrombocytopenia, schistocytosis, hemolytic anemia and renal dysfunction. She underwent treatment with plasmapheresis; however, her response to treatment was poor and died on day 16 of hospitalization. The autopsy performed revealed microthrombi in the glomeruli and tubulonecrosis in the kidneys.
CONCLUSION: This is the first case report of TMA in association with the use of S-1 and cisplatin. Therapists have to take account of TMA when using S-1 and cisplatin treatment. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  S-1; Thrombotic microangiopathy; cisplatin; thrombotic thrombocytic purpura

Mesh:

Substances:

Year:  2017        PMID: 28438876      PMCID: PMC5461458          DOI: 10.21873/invivo.11080

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  10 in total

1.  Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.

Authors:  Pavan K Bendapudi; Ang Li; Ayad Hamdan; Lynne Uhl; Richard Kaufman; Christopher Stowell; Walter Dzik; Robert S Makar
Journal:  Br J Haematol       Date:  2015-08-28       Impact factor: 6.998

Review 2.  Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.

Authors:  Klaus Lechner; Hanna Lena Obermeier
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

Review 3.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 4.  Thrombotic microangiopathy, cancer, and cancer drugs.

Authors:  Hassan Izzedine; Mark A Perazella
Journal:  Am J Kidney Dis       Date:  2015-05-02       Impact factor: 8.860

Review 5.  Drug-induced thrombotic microangiopathy: a systematic review of published reports.

Authors:  Zayd L Al-Nouri; Jessica A Reese; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2014-11-20       Impact factor: 22.113

6.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

8.  Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.

Authors:  Yu Nishijima; Haruhiko Hirata; Aiko Himeno; Hiroshi Kida; Masanori Matsumoto; Ryo Takahashi; Yasushi Otani; Kouji Inoue; Izumi Nagatomo; Yoshito Takeda; Takashi Kijima; Isao Tachibana; Yoshihiro Fujimura; Atsushi Kumanogoh
Journal:  Intern Med       Date:  2013-05-15       Impact factor: 1.271

Review 9.  Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.

Authors:  J B Lesesne; N Rothschild; B Erickson; S Korec; R Sisk; J Keller; M Arbus; P V Woolley; L Chiazze; P S Schein
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

Review 10.  Cancer-associated thrombotic microangiopathy.

Authors:  K Govind Babu; Gita R Bhat
Journal:  Ecancermedicalscience       Date:  2016-06-28
  10 in total
  1 in total

1.  An Update in Drug-Induced Thrombotic Microangiopathy.

Authors:  Thomas Chatzikonstantinou; Maria Gavriilaki; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  Front Med (Lausanne)       Date:  2020-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.